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in bisphosphonate administered 
ovariectomized rats
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The purpose of this study was to investigate the effect of administering intermittent parathyroid 
hormone (iPTH) before tooth extraction versus after tooth extraction on the risk of developing 
MRONJ in experimental animal model. Twenty‑five ovariectomized rats received 6 weeks of 
bisphosphonate therapy. They were classified into 3 groups, based on the timing of the medication, 
as Control, Pre‑PTH and Post‑PTH groups. For Control group, normal saline was administered before 
and after tooth extraction. iPTH was administered during 4 weeks before tooth extraction for Pre‑
PTH group and after tooth extraction for Post‑PTH group. The animals were euthanized 8 weeks 
after tooth extraction. Macroscopic, histological, micro‑computed tomography (micro‑CT), and 
histomorphometric examinations were conducted. The incidences of impaired healing were 11.11% 
both in Pre‑PTH and Post‑PTH groups, which was lower than the Control group (42.86%). Bone 
healing in the extraction socket, based on micro‑CT and histomorphometry evaluations, was best in 
Post‑PTH and worst in Control group. The Pre‑PTH group showed moderate healing pattern. Despite 
of limitations in this study, the authors identified Pre‑PTH group seems to have positive effect on 
extraction socket healing. With regard to timing, administering iPTH after tooth extraction was 
superior to applying it before tooth extraction.
Bisphosphonates (BPs) inhibit bone resorption through several mechanisms such as inhibiting osteoclast forma-
tion and decreasing the bone turnover rate and apoptosis of  osteoclasts1,2. In this regard, BPs have a good effect 
in treating bone metabolic diseases such as osteoporosis or preventing bone metastasis of malignant tumors. 
However, complications such as medication-related osteonecrosis of the jaw (MRONJ) have been reported after 
invasive dental  treatment3.
Despite the complete absence of data showing that discontinuing anti-resorptive medications affects the 
occurrence of MRONJ, discontinuation of BPs is recommended to decrease the risk of MRONJ. A 2014 posi-
tion paper by the American Association of Oral and Maxillofacial Surgery suggested a 2-month cessation of BPs 
as a prudent  approach4,5. In an animal study, Zandi et al.6 reported 3 months of drug cessation might decrease 
incidence decrease of MRONJ development. However, there is still no clear criteria exist for the period of BP 
discontinuation. In addition, discontinuing BPs does not completely prevent MRONJ.
Intermittent parathyroid hormone (iPTH) administration, which has an anabolic effect, is widely used to 
manage intractable  MRONJ7,8. The administration of iPTH with bone morphogenic protein-2 was recently 
reported in the management of  MRONJ9. However, the role of iPTH to prevent MRONJ is relatively unknown, 
compared to its role in treating MRONJ.
Several studies have compared the effect of administering iPTH timing regarding surgical intervention with 
or without previous bisphosphonate treatment; however, the findings of these studies remain  controversial10,11. 
Keskinruzgar et al.10 reported the risk of MRONJ development may decrease when PTH is administered before 
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or immediately after tooth extraction with a greater number of osteoclasts when PTH was administered before or 
immediately after tooth extraction. However, based on the findings of a study by Kuroshima et al.11, no significant 
differences existed when iPTH was administered for the 7 days before tooth extraction and ridge preservation, 
compared with sterile saline injection (i.e., the control group).
The purpose of this study was to compare the effect of iPTH on extraction socket healing according to 
administration timing (i.e. before tooth extraction versus after tooth extraction) in bisphosphonate administered, 
ovariectomized rat model.
Results
Twenty-five rats underwent ovariectomy, followed by an 8-week waiting period. Then, zoledronic acid (200 μg/
kg) was administered for 6 weeks. The bisphosphonate administered, ovariectomized rats were randomly divided 
into three groups: the Control group, Pre-PTH group, and Post-PTH group. 80 μg/kg of parathyroid hormone 
(PTH) was administered daily for 4 weeks before or after tooth extraction according to the experimental groups. 
Same dosage of normal saline was administered when PTH was not administered. The rats were euthanized after 
8 weeks after tooth extraction. No rats were expired during experimental periods.
Effects of iPTH on the development of osteonecrosis of the jaw. The incidence of osteonecrosis 
of the jaw (ONJ) is summarized in Table 1. In macroscopic analysis, three (42.86%) of seven Control group rats 
had ONJ. One (11.11%) of nine rats had ONJ in the Pre-PTH group and in the Post-PTH group, although this 
difference was not statistically significant (p = 0.260). ONJ was histologically diagnosed in four (57.14%) of seven 
Control group rats. The incidence of MRONJ healing was 33.33% and 11.11% in the Pre-PTH and Post-PTH 
groups, respectively. However, the difference was not statistically significant (p = 0.146).
Effects of iPTH on the bone healing of extraction socket. In the micro-CT evaluation, the BV/
TV value was highest in the Post-PTH group (88.65%) and lowest in the Control group (52.26%) and was sig-
nificantly different (p = 0.020). The value of BV/TV in the Pre-PTH group was 74.77% with close to the level of 
significance compare with Control group (p = 0.075) and with no significant difference when compared with 
Post-PTH group (p = 0.237). Tb.N value was higher in the Pre-PTH (2.01/mm) and Post-PTH (1.93/mm) groups 
than in the Control group (1.46/mm), and was also significantly different (p = 0.049). The Tb.Th value showed 
similar tendency with close to the level of significance (p = 0.060). The Tb.Sp value was lowest in the Post-PTH 
group and highest in the Control group with significant difference (p = 0.039) (Fig. 1a–d).
In histomorphometric analysis, B.Ar/T.Ar in the extraction socket was highest in the Post-PTH group 
(94.47%) and lowest in the Control group (55.76%) (Fig. 1e). However, the difference was not significant statis-
tically (p = 0.198).
The micro-CT image of each group was presented in Fig. 2 and the actual data was summarized and presented 
in Table 2.
Effects of iPTH on the trabecular bone of the proximal tibia. The effect of PTH administration on 
the proximal tibia can be found on Supplementary Fig. S1. Compared with the Control group, the Pre-PTH and 
Post-PTH groups had significantly higher values for BV/TV (p = 0.004) and Tb.Th (p = 0.048), and significantly 
lower values for Tb.Sp (p = 0.029). Compared with the Control group, the Pre-PTH group had significant higher 
values for Tb.N (p = 0.002). However, for all parameters, there were no significant differences between the Pre-
PTH and Post-PTH groups (Supplementary Fig. S1b–e).
Discussion
In 2001, Neer et al. reported the anabolic action of iPTH  administration12. Since then, several investigators have 
reported the effectiveness of iPTH on the healing of fractures, after tooth extraction, periodontal healing, and 
in the treatment of  MRONJ7,13–16. Intermittent parathyroid hormone administration could be considered as 
treatment modality for severe MRONJ. However, its effect on preventing MRONJ and extraction socket healing 
remains  unclear16–18.
The purpose of this study was to compare the effect of iPTH on extraction socket healing according to admin-
istration timing (i.e. before tooth extraction versus its effect after tooth extraction) following bisphosphonate 
pre-treatment in experimental animal model. In this study, we considered that macroscopically impaired healing 
as MRONJ to have occurred or may occur in the future.
Table 1.  Incidence of medication-related osteonecrosis of the jaw (MRONJ) development. Administration of 
intermittent PTH seemed to have a positive effect on extraction socket healing both in Pre-PTH and Post-PTH 
groups.
Group
Clinical analysis Histologic assessment
Impaired healing Incidence (%) p-value Impaired healing Incidence (%) p-value
Control (n = 7) 3 42.86
0.260
4 57.14
0.180Pre-PTH (n = 9) 1 11.11 3 33.33
Post-PTH (n = 9) 1 11.11 1 11.11
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Park et al. reported rats had become osteopenic after ovariectomy compared with sham  surgery19. Yoon et al. 
reported bone mass was significantly decreased 8 weeks after ovariectomy in  rats20. Bisphosphonate is a drug for 
the treatment of osteoporosis. The rats underwent ovariectomy and BPs had been started after 8 weeks in order 
to reproduce this condition as much as possible.
Micro-CT analysis of the proximal tibia was conducted to observe the systemic effect of PTH administration. 
The Pre-PTH and Post-PTH groups had significantly higher values for BV/TV, Tb.N, and Tb.Th, and significantly 
lower value for Tb.Sp, compared with those of the Control group (p < 0.05). Thus, the exogenously administered 
PTH appears to have been functioning properly for bone metabolism in ovariectomized rats.
The incidence of ONJ after tooth extraction varies 60–95%, depending on the dose and duration of ZA 
 injection6,10,21–23. In this study, 200 μg/kg of ZA was administered every week (1×/week), according to our previ-
ous  study24. The dosage was decided considering following factors as Kim et al. reported: (1) the oncologically 
relevant zoledronate dosed in humans (67 μg/kg/4 weeks); (2) the relatively rapid bone metabolism of rodents; 
(3) the route of bisphosphonate administration; lower plasma concentration through intraperitoneal injection 
compared with intravenous injection; and (4) maximize exposure to bisphosphonate during relatively short 
experimental  periods24. In the present study, the incidence of osteonecrosis of the jaw was 42.86%, 11.11% 
and 11.11% in the Control group, Pre-PTH group, and Post-PTH group, respectively. After the microscopic 
Figure 1.  Effects on the extraction socket healing related to parathyroid hormone (PTH) administration. 
(a–d) Micro-computed tomography (micro-CT) analysis. In micro-CT analysis, the PTH-administered groups 
showed higher (a) bone volume/tissue volume (BV/TV), (b) trabecular number (Tb.N), and (c) trabecular 
thickness (Tb.Th), and (d) lower trabecular separation (Tb.Sp), compared with the Control group. (e) 
Histomorphometric analysis. The bone area/tissue area (B.Ar/T.Ar) shows a similar pattern as the BV/TV in the 
micro-CT analysis. *p < 0.05, versus the Control.
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evaluation, MRONJ was diagnosed in 57.14%, 33.3%, and 11.1% of the Control group, Pre-PTH group, and 
Post-PTH group, respectively.
The dosage of PTH (80 ug/kg) was determined by reference to the study of Kuroshima et al.25 In their study, 
the reported 80 ug/kg of PTH therapy for 2 weeks after bisphosphonate combined with steroid and tooth extrac-
tion rescued necrotic lesions.
Micro-CT revealed that the degree of bony healing of the extraction socket was greater in the Post-PTH 
group than in the Pre-PTH group, and the degree of healing was significantly greater in these groups than in the 
Control group (p = 0.020). Histomorphometric analysis was conducted to verify the results of micro-CT and to 
confirm the correlation between microscopic analysis and micro-CT. The degree of bone healing observed on 
micro-CT images and with histomorphometric analysis showed a similar tendency, as shown in Fig. 1a,e. The 
degree of bone fill was greater in the extraction socket of the Pre-PTH group (94.47%) than in the Control group 
(55.76%); however, the difference was not significant in histomorphometric analysis (p = 0.198).
Although, histomorphometric analysis revealed no statistically significant difference, the healing pattern 
of the three groups observed with H&E staining showed different tendencies. In the Control group, favorable 
bone healing was observed in cases of “healing”. However, in cases of “MRONJ,” inflammatory cell infiltration 
with necrotic bone or severe surrounding bone destruction was observed. The Pre-PTH group showed varying 
results. The extraction socket healing occurred in mature bone with or without fibrotic tissue formation. The 
extraction socket was filled with inflammatory cells in “ONJ” cases. However, unlike in the Control group, there 
was little evidence of severe bone destruction in Pre-PTH group. Most rats in the Post-PTH group had excellent 
bone healing but without a substantial difference among the animals. Pre-PTH group and Post-PTH group also 
showed osteoclastic activity in extraction socket compared with Control group (Supplementary Fig. S3). We 
consider this phenomenon had an indirect effect of iPTH administration on bone  healing26.
Several studies have compared the effect of administering iPTH before or after surgical intervention with 
or without previous bisphosphonate treatment; however, the findings of these studies remain  controversial10,11. 
Keskinruzgar et al.10 reported a greater number of osteoclasts when PTH was administered before or immedi-
ately after tooth extraction, compared to when only ZA was administered. Keskinruzgar also reported the risk of 
osteonecrosis development may decrease when PTH is administered before or immediately after tooth extraction. 
However, based on the findings of a study by Kuroshima et al.11, no significant differences existed when iPTH was 
administered for the 7 days before tooth extraction and ridge preservation, compared with sterile saline injection 
Figure 2.  Representative images of micro-CT of each group. Insufficient bone healing was observed in control 
group (yellow arrowhead), whereas good bone healing of extraction socket was observed in pre-PTH and post-
PTH groups (white arrow).
Table 2.  Effects on the extraction socket healing related to parathyroid hormone (PTH) administration (The 
actual data of Fig. 1). BV/TV bone volume/tissue volume, Tb.N trabecular number, Tb.Th trabecular thickness, 
Tb.Sp trabecular separation, B.Ar/T.Ar bone area/tissue area. *p < 0.05, versus the Control.
Contol Pre-PTH Post-PTH p-value
Micro-CT analysis
BV/TV (%) 52.26 ± 7.16 74.77 ± 8.67 88.65 ± 6.96* 0.020
Tb.N (1/mm) 1.46 ± 0.15 2.01 ± 0.16* 1.93 ± 0.14* 0.049
Tb.Th (mm) 0.32 ± 0.04 0.36 ± 0.04 0.46 ± 0.04 0.060
Tb.Sp (mm) 0.29 ± 0.03 0.21 ± 0.04 0.13 ± 0.03* 0.039
Histomorphometric analysis
B.Ar/T.Ar (%) 55.76 ± 13.44 70.49 ± 13.29 94.47 ± 14.90 0.198
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(i.e., the control group). On the other hand, iPTH had an effect when administered during the 14-day period 
after the same procedure. Kuroshima reported that dynamic cellular responses such as inflammation after tooth 
extraction may contribute to the anabolic effect of  iPTH11. The anabolic action of PTH is more powerful after 
surgical intervention than in undisturbed bone, and is enhanced where the bone metabolism rate is  high25. We 
propose that the anabolic action of PTH increases because bone metabolism is activated after tooth extraction, 
compared with before tooth extraction.
This study was designed as pre-clinical animal experiment, it may be difficult to apply direct to clinical prac-
tice. It seems that Pre-PTH and Post-PTH group showed better healing tendency and positive effect on bone 
healing compared with control group. With regard to the timing of drug administration, iPTH administered 
after tooth extraction (i.e., Post-PTH group) had a better outcome, compared with iPTH administration before 
extraction (i.e., Pre-PTH group), whereas there was no significant difference when three groups were compared 
simultaneously.
In this study, the sample size was simply determined with reference to other experimental animal  studies10,15. 
Maybe this sample size is not enough to generalize the effect of intermittent PTH administration before tooth 
extraction to prevent MRONJ development. In addition, some investigators have suggested that a low bone 
turnover rate induced by bisphosphonate can reduce the availability of osteoblasts, marrow-lining cells, and pre-
osteoblasts, and the effects of continued bisphosphonate treatment reduce the PTH-induced bone  formation27,28. 
Therefore, it is necessary to discontinue bisphosphonate for a certain period before initiating PTH treatment 
because PTH has a delayed effect when a person is pretreated with  bisphosphonate29.
In the future, studies using a larger number of experimental animals or longer iPTH administration may be 
required.
Materials and methods
Animal model and study design (Fig. 3). Twenty-five female Sprague–Dawley rats (Orientbio Co., 
Ltd. Seongnam, Korea) were used in this study. The mean weight was 232.9 g (range 201–262.5 g). They were 
randomly divided into three groups: the Control group, Pre-PTH group, and Post-PTH group. Animals were 
housed two rats per cage and were individually marked. The cages were placed in a room with filtered air at a 
temperature of 22 ± 2 °C and relative humidity of 50 ± 10%. A 12-h light/dark cycle was maintained. The animals 
were fed a normal rodent diet and water ad libitum. Animals were acclimated for 1 week before the beginning of 
the study. This study was approved by and performed in accordance with the guidelines of the Yonsei University 
Health System Institutional Animal Care and Use Committee (IACUC No. 2017–0063).
All rats were 11 weeks old and underwent ovariectomy at 12 weeks of age. An 8-week waiting period was used 
to induce an osteopenic condition, based on the procedure of Park et al.19 ant Yoon et al.20. Zoledronic acid (ZA; 
200 μg/kg; Zometa Ready, Novartis, Switzerland) was injected into peritoneum for 6 weeks (1×/week, weekly), 
based on the findings in our previous  study24. Then, the rats were divided into three groups as Control group, 
Pre-PTH group and Post-PTH group.
After 6 weeks of ZA administration, an analog of parathyroid hormone (PTH) (Bachem, Torrance, CA, USA), 
was subcutaneously administered daily at a dose of 80 µg/kg in the Pre-PTH group for 4  weeks25. During that 
period, same dose of normal saline was administered for Control and Post-PTH groups. After 4 weeks (at the 
end of PTH injection period in the Pre-PTH group), the left mandibular first (M1) and second molars (M2) 
were extracted, using the procedure reference with previous  protocol24. The movable broken roots were scraped 
once or twice to remove by using a sharp explorer. Excessive forces in extraction socket was avoided as far as 
possible to prevent additional trauma. No other equipment such as a microdrill was used. An additional suture 
was not applied and the extraction socket was left open, as is practiced in human beings. Intramuscular injection 
of meloxicam (1.5 mg/kg body weight; Metacam, Boehringer Ingelheim, Germany) was administered for pain 
control at the time of tooth extraction.
After tooth extraction, PTH analogue (80 μg/kg/day) was administered for 4 weeks. For Control group and 
Pre-PTH group, same dose of normal saline was injected.
Figure 3.  Experimental design. Rats (n = 25) underwent ovariectomy, followed by an 8-week waiting period. 
Zoledronic acid (200 μg/kg) was administered for 6 weeks. Before or after tooth extraction, 80 μg/kg of saline 
or parathyroid hormone (PTH) was administered daily, depending on the group. The parentheses refer to the 
period (weeks) taken for the experiments. BP bisphosphonate.
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Macroscopic evaluation of the extraction socket. All rats were euthanized 8 weeks after the tooth 
extraction. The mandible was dissected and fixed using 10% formalin solution. An extraction socket covered by 
normal mucosa without dehiscence was defined as having a normal healing state. Exposure of the underlying 
bone or mucosal dehiscence was defined as impaired healing, which considered as MRONJ to have occurred or 
may occur in the future. Mucosal hyperemia or granulation tissue formation on the extraction socket was also 
defined as impaired  healing22.
Microscopic computed tomography. Micro-computed tomography (micro-CT; Skyscan 1173, Konitch, 
Belgium) images were scanned at 13.85-μm pixels (for the mandible) and 15.98-μm pixels (for the tibia) with an 
energy level of 90 kV. The data were evaluated using CTAn software (Skyscan, Konitch, Belgium). To assess the 
systemic effect of the administered PTH, the center of trabecular bone between 1.2 and 3.5 mm from the growth 
plate of the proximal tibia was analyzed. The region of interest (ROI) was set as a circle of 2.0 mm × 2.0 mm at 
the 1.2 mm site and a circle of 1.5 mm × 1.5 mm circle at the 3.5 mm site (Supplementary Fig. S2a)25. To evalu-
ate the extraction socket, the ROI was set on the center of the extracted site in the coronal view (Supplementary 
Fig. S2b). Seventy images of the M2 distal root (0.7 mm × 0.7 mm circle) and M1 distal root (1.0 × 1.0 mm circle), 
and 80 images of the M1 mesial root (0.8 mm × 0.8 mm circle) were analyzed with regard to the mesiodistal 
length of each root. Bone volume/tissue volume (BV/TV [%]), trabecular number (Tb.N [1/mm]), trabecular 
thickness (Tb.Th [mm]), trabecular separation (Tb.Sp [mm]), and bone marrow density were assessed in each 
group.
Histology and histomorphometry. All specimens were fixed with 10% formalin solution for 2 weeks 
and decalcified in 10% ethylenediaminetetraacetic acid (pH 7.4) for 3 weeks at room temperature. Samples were 
embedded in paraffin and sectioned with 3-μm thickness. Samples were stained with hematoxylin and eosin 
(H&E). Imparied healing was diagnosed if any of the following criteria were met: (1) the presence of an ulcera-
tive lesion with exposed and necrotic bone and/or osteolysis, (2) the presence of pseudoepitheliomatous-like 
hyperplasia of the epithelium accompanied by inflammatory cell infiltration, and (3) the presence of sequestrum 
and bacterial  colonies24. An ulcerative lesion was defined when the epithelium on the extraction socket was not 
fully covered (Fig. 4a–d).
Images were captured using a microscope (Axio Imager 2; Zeiss, Göttingen, Germany) and analyzed with 
image analysis software (MetaMorph, ver 7.8; Molecular Devices, Sunnyvale, CA, USA). Histomorphometric 
evaluation was focused on the extraction socket areas. The tissue area (T.Ar  [mm2]) and bone area (B.Ar  [mm2]) 
were measured. The B.Ar/T.Ar ratio (%) was calculated to normalize the parameters.
Statistical analysis. Statistical analysis was conducted using a statistical software program (SPSS 23.0; 
IBM, Armonk, NY). Mucosal healing at the macroscopic and microscopic levels was compared using Fisher’s 
exact test. In the micro-CT analysis of tibia, one-way ANOVA was used to compare the 3 groups when the distri-
bution satisfied the normality assumption. Otherwise, the Kruskal–Wallis test was used to compare the groups. 
Post-hoc test with Bonferroni’s method was performed to compare groups in case of significant difference after 
ANOVA. In the micro-CT analysis and histomorphometric analysis of mandible, mixed model was used to 
compare the 3 groups. Pairwise comparison was performed with LSD method. Values of p < 0.05 indicated a 
significant difference and 0.05 ≤ p < 0.1 was considered a trend close to significance to increase the sensitivity to 
detect potential selection bias.
Figure 4.  Representative images of (a,b) healing and (c,d) MRONJ, based on hematoxylin and eosin (H&E) 
staining (magnified × 50). (a,b) The extraction socket is filled with bone completely or partially (asterisk mark). 
Black arrow indicates fibrotic healing states. (c) The extraction socket shows impaired healing with ulcerative 
epithelium (arrowhead) and necrotic bone (N). (d) The extraction socket is filled with inflammatory cells, 
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Conclusion
Despite of limitations in this study, the authors identified iPTH administration before tooth extraction seems 
to have a positive effect on extraction socket healing. With regard to timing, administering iPTH after tooth 
extraction was superior to applying it before tooth extraction.
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